Back to results
US 9,956,281 B2Granted
Inactivated virus compositions and methods of preparing such compositions
AssigneeStreck, Inc.
InventorsWayne L. Ryan, James A Grunkemeyer
Life of this patent
Estimating the term…
Abstract
The present invention is directed at a composition comprising a live swine flu virus having an infectious component and a plurality of surface antigens in contact with a formaldehyde donor agent having a molecular weight that is less than about 400 g/mol. Preferably, the formaldehyde donor agent is selected from a non-crosslinking chemical fixative that contains urea.
Claims15
A method comprising the steps of:
- a) providing a live swine flu virus having an infectious component and a plurality of surface antigens;
- b) contacting the live swine flu virus with a non-crosslinking chemical fixative that contains at least one urea-based formaldehyde donor agent having a molecular weight that is greater than 50 g/mol and less than 400 g/mol for de-activating the infectious component with the at least one urea-based formaldehyde donor agent, and for preserving at least a portion of the plurality of surface antigens sufficient to induce an immune response to form an antigen-treated deactivated virus composition such that a hemagglutination activity of the antigen-treated deactivated virus composition is retained for a period of at least 6 months;
- and
- c) storing and/or transporting the antigen-treated deactivated virus composition at ambient temperature from about 25° C. to about 37° C. without cold storage or transport.
1 more element
A method for de-activating a live swine flu virus and retaining hemagglutination activity comprising the steps of:
- a) providing a live swine flu virus having an infectious component and a plurality of surface antigens;
- b) contacting the live swine flu virus with a urea-based formaldehyde donor agent having a molecular weight that is greater than 50 g/mol and less than 400 g/mol for de-activating the infectious component with the at least one urea-based formaldehyde donor agent, and for preserving at least a portion of the plurality of surface antigens to form an antigen-treated deactivated virus composition;
- c) transporting and/or storing the antigen-treated deactivated virus composition at ambient temperature from about 25° C. to about 37° C. without cold storage or transport;
- and
- d) performing a hemagglutination activity (HA) assay to confirm hemagglutination activity of a sample of the transported and/or stored antigen-treated deactivated virus composition.
2 more elements
Dependencies are inferred from the claim text.